A problem for Amarin has been that Vascepa is TOO EFFECTIVE in reducing CVD for adults...An argument could be made that nearly ALL ADULTS (except those with arrythmias or bleeding tendencies) should be taking Vascepa...This would appear to very expensive to governments, which support national health care systems, especially during difficult financial periods....Of course, in the long run, cash paid out by governments for Vascepa would have to be spent in even larger amounts for hospital bills{not to mention those countrymen, who would die from avoidable CVD)
The logical solution to this conundrum is for such a safe and effective drug as Vascepa to be marketed to as large population as possible for as low a price as possible...In order to accomplish this, Amarin should....
-Put Vascepa in the hands of a large Pharma with multinational marketing abilities, that would...
-Market an authorized generic Vascepa in the U.S.
-Keep the price of Vascepa low worldwide
-Start to investigate sources of supply of API from other sources than just fish(e.g.algae)
Market Data 
Markets 
